Ambu AS (OTCPK:AMBFF)
$ 19.9 -0.6 (-2.93%) Market Cap: 4.14 Bil Enterprise Value: 4.14 Bil PE Ratio: 123.69 PB Ratio: 5.18 GF Score: 97/100

Q4 2024 Ambu A/S Earnings Call Transcript

Nov 05, 2024 / 09:00AM GMT
Release Date Price: $19.9
Britt Meelby Jensen Ambu A;S;CEO

/-

Hello everyone and welcome to this call where we from Amber will present our Q4 and full year results from our fiscal year 2,324.

The agenda for today is that we will first present our results on the business and the financials and then we will hand over to the operator to moderate the Q&A session.

I'm Breg Milian and I'm the CEO of Ambu. And with me today, I have Henrik Sbender, our CFO.

So let's dive into the results from our Q4 and the full year in Q4, we delivered 10.6% revenue growth split into 4.5% growth in organic revenue growth in endoscopy and 4.3% in anesthesia and patient monitoring.

In terms of profitability, we had an ebit margin also amounting to 10.6%. And then we had a positive cash flow of DKK98 million for the full year. This means that in terms of revenue growth, we delivered 13.8% and this was mainly driven by endoscopy where we grew 19.7%.

So this strong performance comes after a year where we have had a lot of momentum in the business at Ambu. And where I'm grateful for the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot